mdlinx mdlinx
Latest (92) Full Text Articles (1945) Focus on Other GI Infections Article Summary

Pharmacokinetics and Pharmacodynamics of Once-Daily versus Twice-Daily Raltegravir in Treatment-Naïve HIV-Infected Patients
Antimicrobial Agents and Chemotherapy,  Clinical Article

Rizk ML et al. – With QD dosing, Ctrough values correlated with the likelihood of virologic response. Failure to achieve an HIV RNA level of <50 copies/ml appeared predominantly at high baseline HIV RNA levels in both treatment arms and was associated with lower values of GM Ctrough in the 800–mg–QD arm, though other possible drivers of efficacy, such as time above a threshold concentration, could not be evaluated due to the sparse sampling scheme. Together, these findings emphasize the importance of the shape of the plasma concentration–versus–time curve for long–term efficacy.

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

    Currently, there are no available articles.

Your Unread Messages in Infectious Disease

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Infectious Disease Articles

Last month's top read Top Articles of 2013

Indexed Journals in Infectious Disease: Journal of Infection, AIDS, American Journal of Infection Controlmore

Other Topics in Infectious Disease

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Stay current - Media Tool

Newsletter
RSS
Follow
Like

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close